Current Treatment Options in Oncology最新文献_第7页

Evolving Landscape of HER2-Targeted Therapies for Gastric Cancer Patients. 针对胃癌患者的 HER2 靶向疗法不断发展。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-04-01 Epub Date: 2025-03-08 DOI: 10.1007/s11864-025-01300-0

Lijuan He, Ben Liu, Zhuanfang Wang, Qinying Han, Hao Chen

{"title":"Evolving Landscape of HER2-Targeted Therapies for Gastric Cancer Patients.","authors":"Lijuan He, Ben Liu, Zhuanfang Wang, Qinying Han, Hao Chen","doi":"10.1007/s11864-025-01300-0","DOIUrl":"10.1007/s11864-025-01300-0","url":null,"abstract":"Opinion statement: Gastric cancer (GC) is a deadly disease worldwide, and trastuzumab in combination with chemotherapy has been the standard first-line treatment for HER2-positive GC following the TOGA trial. Besides adjuvant therapy, HER2-directed therapy is widely used as neoadjuvant or translational therapy, and survival benefit even surgical opportunities is seen in these patients. However, resistance is not rare in recent years, and the second-line treatment for trastuzumab beyond progression has received widespread attention in GC. Moreover, current evidence cannot recommend trastuzumab for patients with IHC1+ HER2 low expression GC yet. Researchers are currently investigating whether GC patients with low HER2 expression could also benefit from HER2-directed therapies. In addition to using HER2 as a target for targeted therapy, HER2-mediated targeted delivery of cytotoxic drugs and targeted immunity have made important contributions to overcoming trastuzumab resistance in recent trials. HER2/neu-derived peptide epitopes vaccination and HER2-specific chimeric antigen receptor (CAR) therapy focus on reestablishing anti-tumor immunity in different ways and show significant anti-tumor activity. Other antibodies that target different regions of the HER2 receptor or block key downstream pathways such as AKT or PI3K also offer potential anti-tumor activity against HER2. HER2 use in GC will not be hampered by resistance or low expression and will play a bigger role. We review the current efforts to enable GC patients with trastuzumab-resistant and HER2 low-expressing accessible to HER2 targeted therapy and present our consideration for future HER2 in GC.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"260-277"},"PeriodicalIF":3.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143582400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in Personalized Treatment and Prognostic Factors of Follicular Lymphoma. 滤泡性淋巴瘤个体化治疗及预后因素研究进展。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-04-01 Epub Date: 2025-04-02 DOI: 10.1007/s11864-025-01297-6

Shijia Cheng, Yanyan Liu

引用次数: 0

Impact of Genetic Polymorphisms on Treatment Outcomes of Proteasome Inhibitors and Immunomodulatory Drugs in Multiple Myeloma. 遗传多态性对多发性骨髓瘤中蛋白酶体抑制剂和免疫调节药物治疗结果的影响。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-03-01 Epub Date: 2025-03-05 DOI: 10.1007/s11864-025-01295-8

Fatemeh Karimi, Mojtaba Aghaei, Najmaldin Saki

引用次数: 0

Taxane-Associated Acute Pain Syndrome: a Review of its Features and Management. 紫杉烷相关急性疼痛综合征：其特征和治疗的综述。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-03-01 Epub Date: 2025-02-28 DOI: 10.1007/s11864-025-01302-y

Yoshitaka Saito

{"title":"Taxane-Associated Acute Pain Syndrome: a Review of its Features and Management.","authors":"Yoshitaka Saito","doi":"10.1007/s11864-025-01302-y","DOIUrl":"10.1007/s11864-025-01302-y","url":null,"abstract":"Opinion statement: Taxane-associated acute pain syndrome (T-APS) is one of the most common adverse effects of taxane treatment and significantly reduces the quality of life and activities of daily living of patients. T-APS is recognized as myalgia and arthralgia, which generally appear 1-3 days after taxane administration and last for approximately 7 days, at a wide range of sites. Recently, T-APS has been suggested to be not only an acute symptom but also a chronic symptom associated with chemotherapy-induced peripheral neuropathy (CIPN). The reported incidence of T-APS varies among studies, possibly owing to differences in observation points, evaluation methods, taxane administration methods, concomitant medications, or patient factors. Several factors, such as high taxane dose, paclitaxel use, metastatic setting, breast cancer, younger age, and co-administration of pegfilgrastim, are associated with symptom development. Several findings regarding T-APS management, such as prophylaxis using corticosteroids, Shakuyaku-Kanzo-to, and non-steroidal anti-inflammatory drugs (NSAIDs), are present. Corticosteroids for several days after taxane administration dose-dependently prevents and attenuates T-APS although we should be cautious about its longer administration. Prophylactic administration of Shakuyaku-Kanzo-to, a herbal compound, may be useful, although prescriptions are only available in limited areas. Etoricoxib, a selective cyclooxygenase-2 inhibiting NSAID, also reduces the incidence and severity of T-APS. Additionally, its prophylactic administration decreases CIPN. In contrast, evidence of symptomatic medication is limited. Taxanes are key chemotherapeutic agents used in the treatment of several types of cancer; therefore, further assessment of mechanisms of action and treatment of T-APS is necessary.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"187-196"},"PeriodicalIF":3.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143525052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fertility Sparing Medical Management Options in Gynecologic Cancers. 妇科癌症保留生育能力的医疗管理选择。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-03-01 Epub Date: 2025-02-19 DOI: 10.1007/s11864-025-01299-4

Ana Kouri, Janelle P Darby

{"title":"Fertility Sparing Medical Management Options in Gynecologic Cancers.","authors":"Ana Kouri, Janelle P Darby","doi":"10.1007/s11864-025-01299-4","DOIUrl":"10.1007/s11864-025-01299-4","url":null,"abstract":"Opinion statement: There is an increasing use of medical management for gynecologic cancers given the rise in neoadjuvant therapies, delayed childbearing, and use of assisted reproductive technology. Chemotherapy, albeit broadly used in most gynecologic cancers, lacks long term data with respect to its associated gonadotoxicity and potential adverse pregnancy outcomes. Immunotherapy and other targeted therapies that have demonstrated promising responses in other tumor types are increasingly being studied in gynecologic malignancies. These therapies may offer opportunities for enhanced treatment response in an effort to minimize more toxic, invasive, or surgical management approaches that could have significant negative implications on fertility. Given that some of these therapies do not represent the standard of care and currently only exist in the experimental setting, detailed counseling and careful selection of patients for fertility sparing treatment remains critical. It is reasonable for patients with early stage, low-risk endometrial cancers to attempt conservative management while establishing clear treatment objectives. Early involvement of fertility specialists is necessary in order to optimize these patients' pregnancy goals. An emphasis on lifestyle changes and in particular weight loss should also be discussed with these patients. Neoadjuvant chemotherapy followed by fertility sparing surgery in cervix cancer patients with low-risk, small tumors shows promising results that suggest this can be a safe treatment option. Patients with advanced stage disease of any primary tumor or aggressive histology such as in many cases of ovarian cancer are not appropriate candidates for prioritization of fertility sparing treatment options. Ongoing and future studies will help to better identify appropriate patients and maximize medical management options in early-stage gynecologic cancers.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"157-166"},"PeriodicalIF":3.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11919979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143450349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gynecologic Cancer Screening and Prevention: State of the Science and Practice. 妇科癌症筛查与预防：科学与实践的现状。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-03-01 Epub Date: 2025-02-27 DOI: 10.1007/s11864-025-01301-z

C Tran, H Diaz-Ayllon, D Abulez, S Chinta, M Y Williams-Brown, N Desravines

{"title":"Gynecologic Cancer Screening and Prevention: State of the Science and Practice.","authors":"C Tran, H Diaz-Ayllon, D Abulez, S Chinta, M Y Williams-Brown, N Desravines","doi":"10.1007/s11864-025-01301-z","DOIUrl":"10.1007/s11864-025-01301-z","url":null,"abstract":"Opinion statement: Gynecological cancers, including cervical, endometrial, ovarian, and vulvovaginal cancer, have increasing incidence and mortality globally over the last three decades. In that time, there have been advances in medical therapies and paradigm shifts in surgical treatment which have resulted in a greater quality of life for patients. Clinicians have also refocused efforts to preventing gynecologic cancer. The state of screening and prevention is varied in each of the cancer types. The most comprehensive screening program and only preventable gynecological cancer is cervical cancer, which has been heavily studied since the 1900s. Cervical cytology, primary high-risk human papillomavirus (HPV) testing only, and co-testing are all effective in detecting cervical dysplasia and touted by the major medical. An additional arsenal is prevention through vaccination which has been shown to decrease cervical cancer. Unfortunately, the other gynecological cancers do not have effective screening strategies. The high rates of symptoms in endometrial cancer facilitate detection at an early stage but thus far, asymptomatic screening is only advocated in very high-risk population due to the invasive nature. Novel non-invasive mechanisms are currently under study though none have translated into clinical practice as of yet. Ovarian cancer remains the most innocuous with vague symptoms at onset resulting in late-stage diagnosis. Recommendations for prophylactic oophorectomy only apply to subsets of the population with predisposing genetic mutations. This has led to an ardent push for creative strategies such as opportunistic salpingectomy and a national genetic screening program. These efforts are in addition to the investigations underway researching radiologic, liquid biopsy, and genetic marker screening modalities for all gynecologic cancer. This review article discusses the state of screening, prevention, and recent advancements and pilot studies for each gynecological cancer.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"167-178"},"PeriodicalIF":3.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Updates in Hormone Replacement Therapy for Survivors of Gynecologic Cancers. 妇科癌症幸存者激素替代疗法的最新进展。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-03-01 Epub Date: 2025-03-05 DOI: 10.1007/s11864-025-01298-5

Megan Gorman, Karin Shih

{"title":"Updates in Hormone Replacement Therapy for Survivors of Gynecologic Cancers.","authors":"Megan Gorman, Karin Shih","doi":"10.1007/s11864-025-01298-5","DOIUrl":"10.1007/s11864-025-01298-5","url":null,"abstract":"Opinion statement: Symptoms of menopause and the sequelae of gynecologic cancer treatment can be severe in their physical and mental impact on patient quality of life. Survivors of certain gynecologic cancers - namely, early-stage, low-grade endometrial cancers; epithelial and germ cell ovarian cancers; and early-stage squamous cell cervical, vulvar, and vaginal cancers - as well as those who have undergone risk-reducing surgery for BRCA or Lynch syndrome mutations may safely use hormone replacement therapy (HRT). Treatment is ideally initiated in patients younger than age 60 or within ten years of menopause. The decision to start treatment should be made on an individualized basis after discussion of risks, benefits, and symptom severity with patients. Data suggest that the safest HRT regimens in this population include low-dose vaginal estrogen for the treatment of vulvovaginal symptoms, or low-dose systemic estrogen for the treatment of vasomotor symptoms, combined with progesterone in patients with an intact uterus. Therapies such as SSRIs/SNRIs, vaginal moisturizers, pelvic floor physical therapy, and psychosocial counseling should also be considered when appropriate for their effectiveness in managing menopausal symptoms without the potential risk of hormones.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"179-186"},"PeriodicalIF":3.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11919963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancing Colorectal Cancer Treatment Through VEGF/VEGFR Inhibitors and Immunotherapy. 通过VEGF/VEGFR抑制剂和免疫治疗增强结直肠癌的治疗。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-03-01 Epub Date: 2025-03-06 DOI: 10.1007/s11864-025-01306-8

Jing Jiao, You Wu, Shaoxian Wu, Jingting Jiang

{"title":"Enhancing Colorectal Cancer Treatment Through VEGF/VEGFR Inhibitors and Immunotherapy.","authors":"Jing Jiao, You Wu, Shaoxian Wu, Jingting Jiang","doi":"10.1007/s11864-025-01306-8","DOIUrl":"10.1007/s11864-025-01306-8","url":null,"abstract":"Opinion statement: Colorectal cancer, ranking as the third most prevalent malignancy globally, substantially benefits from both immunotherapy and VEGF/VEGFR inhibitors. Nevertheless, the use of monotherapy proves inadequate in effectively tackling the heterogeneity of tumors and the intricacies of their microenvironment, frequently leading to drug resistance and immune evasion. This situation underscores the pressing need for innovative strategies aimed at augmenting the effectiveness and durability of treatments. Clinical research demonstrates that the combination of VEGF/VEGFR inhibitors (primarily including VEGF/VEGFR-targeted drugs and multi-kinase inhibitors) with immune checkpoint inhibitors creates a synergistic effect in the treatment of colorectal cancer. Our analysis explores how VEGF/VEGFR inhibitors recalibrate the tumor microenvironment, modulate immune cell functions, and influence the expression of immune checkpoints and cytokines. Furthermore, we critically evaluate the preclinical and clinical feasibility of these combined therapeutic approaches. Despite the potential for toxicity, the significant benefits and prospective applications of these strategies warrant thorough exploration. Exploring the synergistic mechanisms of these combined treatments has the potential to inaugurate a new paradigm in oncology, enabling more personalized and efficacious treatment modalities. Additionally, the synergy between VEGF/VEGFR inhibitors and nascent immunotherapies emerges as a promising field of inquiry.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"213-225"},"PeriodicalIF":3.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Metastatic Hormone-Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy. 修正：双重和三重治疗时代的转移性激素敏感前列腺癌。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-02-01 DOI: 10.1007/s11864-025-01294-9

Anthony V Serritella, Maha Hussain

引用次数: 0

Advancements in Diagnosis and Treatment of Cardiac Sarcomas: A Comprehensive Review. 心脏肉瘤的诊断和治疗进展综述。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-02-01 Epub Date: 2025-01-31 DOI: 10.1007/s11864-024-01287-0

Xuezhe Wang, Xinchi Luan, Wenwen Yin, Yilin Wang, Xiaoxuan Li, Ruolan Chen, Guoliang Zhang, Ruizhe Zhao, Xue Dong, Zhishang Zhang, Yuchen Fan, Zhaodong Li, Xianming Chu, Shuang Wang

{"title":"Advancements in Diagnosis and Treatment of Cardiac Sarcomas: A Comprehensive Review.","authors":"Xuezhe Wang, Xinchi Luan, Wenwen Yin, Yilin Wang, Xiaoxuan Li, Ruolan Chen, Guoliang Zhang, Ruizhe Zhao, Xue Dong, Zhishang Zhang, Yuchen Fan, Zhaodong Li, Xianming Chu, Shuang Wang","doi":"10.1007/s11864-024-01287-0","DOIUrl":"10.1007/s11864-024-01287-0","url":null,"abstract":"Opinion statement: Cardiac sarcomas are rare, aggressive malignancies originating from various cardiac cell types, presenting significant challenges in both diagnosis and treatment. This comprehensive review explores recent advancements in diagnosis and treatment of cardiac angiosarcoma, fibrosarcoma, leiomyosarcoma, and rhabdomyosarcoma. And we briefly discuss the exceedingly rare occurrence of cardiac osteosarcoma and present our perspectives on its treatment. Development of these tumors is influenced by genetic mutations, environmental factors, and chromosomal abnormalities, necessitating a multidisciplinary approach for accurate diagnosis and management. Advanced imaging techniques, biomarkers, and immunohistochemical analysis assist in confirming the diagnosis and guiding treatment decisions. Surgical resection, adjuvant therapies, and personalized treatment strategies based on genetic profiling offer promising avenues for improving patient outcomes. Emerging therapeutic approaches, such as targeted therapies and immunotherapies, have shown promising progress in recent years. Despite these advancements, the prognosis for patient with cardiac sarcomas remains poor, highlighting the urgent need for continued research to refine treatment methods and enhance long-term survival outcomes. Ongoing efforts and clinical trials are essential for advancing the management of these rare and aggressive tumors, ultimately improving quality of life for affected patients.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"103-127"},"PeriodicalIF":3.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0